Takeda gets Arogaya CIBioD Innovation and Enterprise Leadership Award
Takeda was recognised for its holistic initiatives, including the 'Blueprint for rare diseases' initiative designed for multi-stakeholder engagement and collaboration focused on rare diseases in India
Takeda India has been awarded the Arogaya CIBioD Innovation and Enterprise Leadership Award at the Tech4Seva Summit. The award was received for the company’s holistic initiatives designed to improve the quality of life and standards of care for patients, including the ‘Blueprint for rare diseases’ initiative.
The awarding body, The Center for Innovation and BioDesign (CIBioD), is an initiative of the Indian Council of Medical Research (ICMR) aimed at promoting research, innovation, and entrepreneurship in the Indian Healthcare System. The award was received at the Tech4Seva Summit, which acts as a platform to mobilise the creative abilities of technology providers from stakeholders to provide scientific and sustainable solutions to the issues that are identified at a grassroots level.
Commenting on the recognition, Simon Gallagher, (Interim) General Manager for Takeda India, said, “At Takeda, we believe in the power of Public-Private Partnerships and innovations to broaden patient access to treatment and care in a sustainable way. By leveraging our internal research capabilities while also actively engaging with innovative ecosystems around us, we remain committed to translating science into highly transformative solutions for the joint better health of the nation.”
He continued, “With the same spirit, we recently conceptualised our ‘Blueprint for rare diseases’ initiative. We aim to go beyond identifying access gaps and their potential solutions and instead enable participants to commit to concrete plans of action to achieve these solutions. The honour motivates us to do more for healthcare systems of the world and aim to help patients lead the best quality of life possible.”
Takeda’s ‘Blueprint for rare diseases’ initiative was pioneered together with relevant stakeholders in the healthcare value chain, including the Ministry of Health – central and state, Patient Groups, notified Centre of Excellence, NGOs, and industry bodies. As a part of this initiative, a charter would be developed for stakeholders to commit to improving care and management of Lysosomal Storage Diseases (LSDs) in evolving healthcare systems. The company has also developed innovative technology-based solutions to improve easy access and coverage to healthcare by connecting healthcare providers and patients.
- Advertisement -